Blog
RSS FeedPosted by Michael Wonder on 20 Jun 2022
HIRA reviews reimbursing antidiabetic combo therapies
15 June 2022 - HIRA has been analysing how new reimbursements for anti-diabetic combination therapies mixing oral SGLT-2 and DPP-4 ...
Posted by Michael Wonder on 26 May 2022
Janssen’s psoriatic arthritis drug Tremfya gets insurance coverage
26 May 2022 - Janssen Korea said that the Ministry of Health and Welfare would begin to reimburse Tremfya, its ...
Posted by Michael Wonder on 19 May 2022
BMS’ Sprycel reimbursement criteria to be broadened for paediatric Philadelphia chromosome positive ALL
19 May 2022 - The state health insurance review agency said it would broaden the reimbursement criteria for Sprycel (dasatinib), ...
Posted by Michael Wonder on 16 May 2022
Korea clears permit for Samsung Bioepis’ Lucentis biosimilar after US
16 May 2022 - Samsung Bioepis received marketing approval for Amelivu (ranibizumab), a biosimilar referencing Lucentis to treat various eye ...
Posted by Michael Wonder on 15 May 2022
Digital health devices must prove a benefit to get reimbursement
13 May 2022 - Digital health care companies should prove that their devices can improve the quality of patient care ...
Posted by Michael Wonder on 10 May 2022
Fertility drug Rekovelle gets reimbursable in combo with hMG
10 May 2022 - Ferring’s Rekovelle (follitropin delta), a treatment to promote egg production in ovaries, became reimbursable when used ...
Posted by Michael Wonder on 10 May 2022
HIRA unveils detailed reimbursement criteria for Olumiant, Rinvoq
10 May 2022 - Lilly’s Olumiant (baricitinib) and Abbvie’s Rinvoq (upadacitinib) got health insurance benefits starting from May 1 to ...
Posted by Michael Wonder on 02 May 2022
Prices of Tecentriq, Avastin go down due to broader insurance benefits
2 May 2022 - The Government granted health insurance benefits to the combination therapy of Tecentriq and Avastin to treat ...
Posted by Michael Wonder on 02 May 2022
Gilead Science’s hepatitis B drug Vemlidy gets expanded insurance benefit
2 May 2022 - Gilead Science Korea said its hepatitis B treatment Vemlidy (tenofovir alafenamide) started receiving expanded health insurance ...
Posted by Michael Wonder on 25 Apr 2022
Is it best to remove insurance benefits from drugs prescribed in bribery?
25 April 2022 - The Ministry of Health and Welfare’s Health Insurance Policy Review Committee is scheduled to hold a ...
Posted by Michael Wonder on 16 Apr 2022
When will SMA oral drug Evrysdi get insurance benefits?
14 April 2022 - Roche’s new spinal muscular atrophy oral treatment Evrysdi (risdiplam) proved the benefit of convenience and cost ...
Posted by Michael Wonder on 11 Apr 2022
Pfizer’s ALK targeted therapy Lorviqua passes reimbursement review
8 April 2022 - Pfizer’s Lorviqua (lorlatinib), a third generation anaplastic lymphoma kinase (ALK) targeted therapy, passed the review for ...
Posted by Michael Wonder on 07 Apr 2022
BeiGene’s Brukinsa quickly passes HIRA’s reimbursement review
7 April 2022 - BeiGene’s Brukinsa (zanubrutinib), a next-generation BTK inhibitor, passed the Health Insurance Review and Assessment Service’s Cancer ...
Posted by Michael Wonder on 05 Apr 2022
Rights watchdog urges quick reimbursement of expensive new drugs
5 April 2022 - The National Human Rights Commission of Korea welcomed the recent reimbursement of CAR-T cell therapy Kymriah ...
Posted by Michael Wonder on 30 Mar 2022
Roche, Government miss deadline for Tecentriq reimbursement talks
30 March 2022 - Roche Korea and the Government failed to reach an agreement over the reimbursement rate of Tecentriq ...